MSB 7.69% $1.19 mesoblast limited

Ann: Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment, page-248

  1. 944 Posts.
    lightbulb Created with Sketch. 299
    A profit is still a profit. Mine is still paper mad.png.

    The C19 excuse for the delay in CLBP and CHF appear dubious to me so I kind of share some of you concern on that front. On the other hand, it is almost biotech 101 that these companies are overly optimistic on their timelines.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.